Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 11;14(22):4775.
doi: 10.3390/nu14224775.

The Role of Dietary Fibers in the Management of IBD Symptoms

Affiliations
Review

The Role of Dietary Fibers in the Management of IBD Symptoms

Claudia Di Rosa et al. Nutrients. .

Abstract

Inflammatory bowel diseases (IBDs) are chronic, progressive, immune-mediated diseases of the intestinal tract. The main subtypes of IBDs are Chron's disease (CD) and ulcerative colitis (UC). The etiology is still unclear, but there are genetic, environmental and host-related factors that contribute to the development of these diseases. Recent literature has shown that dietary therapy is the cornerstone of IBD treatment in terms of management of symptoms, relapse and care of the pathology. IBD patients show that microbiota dysbiosis and diet, especially dietary fiber, can modulate its composition. These patients are more at risk of energy protein malnutrition than the general population and are deficient in micronutrients. So far, no dietary component is considered responsible for IBD and there is not a specific therapeutic diet for it. The aim of this review is to evaluate the role of dietary fibers in CD and UC and help health professionals in the nutritional management of these pathologies. Further studies are necessary to determine the appropriate amount and type of fiber to suggest in the case of IBD to ameliorate psychosocial conditions and patients' quality of life.

Keywords: dietary fibers; inflammatory bowel disease; nutrition.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Agrawal M., Spencer E.A., Colombei J.-F., Ungaro C. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161:47–65. doi: 10.1053/j.gastro.2021.04.063. - DOI - PMC - PubMed
    1. Cohen A.N., Rubin D.T. New Targets in Inflammatory Bowel Disease Therapy: 2021. Curr. Opin. Gastroenterol. 2021;37:357–363. doi: 10.1097/MOG.0000000000000740. - DOI - PMC - PubMed
    1. Zhao M., Gönczi L., Lakatos P.L., Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J. Crohn’s Colitis. 2021;15:1573–1587. doi: 10.1093/ecco-jcc/jjab029. - DOI - PubMed
    1. Flynn S., Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. Surg. Clin. N Am. 2019;99:1051–1062. doi: 10.1016/j.suc.2019.08.001. - DOI - PubMed
    1. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001;411:603–606. doi: 10.1038/35079114. - DOI - PubMed